Invus portfolio
Invus has 25 portfolio companies on record at Recent Funding, with 9 investments in the last 12 months.
About this page
It is a crossover fund based in New York, US, founded in 1985. It led 1 of the 24 rounds it joined. Its most recent investment on record is Soufflé Therapeutics's $135M Series B+ round in October 2026, alongside TAS Partners, Leaps by Bayer, Vida Ventures and 6 others. By category, its portfolio leans toward Health and bio (17) and Logistics and mobility (4). It has co-invested with RA Capital Management, GV and ARCH Venture Partners, most often RA Capital Management (6 rounds).
About Invus
What Invus invests in
- Health and bio · 17 · 68%
- Logistics and mobility · 4 · 16%
- Consumer and social · 3 · 12%
- Data and analytics · 3 · 12%
- Developer tools and cloud · 2 · 8%
- Fintech · 2 · 8%
- Robotics and hardware · 1 · 4%
- Manufacturing and industrial · 1 · 4%
Invus recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Series B+ · $135M | TAS Partners, Leaps by Bayer, Vida Ventures +6 | ||
| Series A · $100M | Firgun (lead), IAG Capital Partners, Eigenstate.holdings +6 | ||
| Series B+ · $150M | Access Biotechnology, Digitalis Ventures, BOLD Longevity Growth Fund +6 | ||
| Series B+ · $250M | Pershing Square Inc. (lead), Korea Investment Partners, Duquesne Family Office +6 | ||
| Series B+ · $75M | Milky Way Investments (lead), ARCH Venture Partners, LoLa Capital Partners +5 | ||
| Series B+ · $99.5M | Viking Global Investors (lead), Casdin Capital, Slate Path Capital +6 | ||
| Series B+ · $92.5M | Biotechnology Value Fund (lead), RA Capital Management (lead), Lumira Ventures +1 | ||
| Series B+ · $287M | SilverArc Capital, Hengdian Group, Adage Capital Management +6 |
How Invus invests
Invus portfolio companies
SSoufflé Therapeutics$135MSeries B+ · Oct 2026
UUniversal Quantum$100MSeries A · Oct 2026
MMatchpoint Therapeutics$150MSeries B+ · Oct 2026
PPrecision Neuroscience$250MSeries B+ · Sep 2026
LLifeMine Therapeutics$75MSeries B+ · Aug 2026
CCity Therapeutics$99.5MSeries B+ · Jun 2026
CContraline$92.5MSeries B+ · Jun 2026
CCorxel$287MSeries B+ · Jan 2026TTriana Bio$120MSeries B+ · Dec 2025
RRapido$200MSeries B+ · Sep 2024
CCardurion Pharmaceuticals$260MSeries B+ · Jul 2024
BBright Peak Therapeutics$90MSeries B+ · Jun 2024
OOrbital Therapeutics$270MSeries A · Apr 2023
FFlare TherapeuticsSeries B+ · Mar 2023
NNoema Pharma$112MSeries B+ · Mar 2023
MMOMA Therapeutics$150MSeries B+ · May 2022
Ddbt Labs$222MSeries B+ · Feb 2022
AAsher Bio$108MSeries B+ · Sep 2021
BBooster$56MSeries B+ · Jun 2019
EEliseAIbacker
PPayhawkbacker
MMirador Therapeuticsbacker
DDorsiabacker
BBrexbacker
WWithinbacker
| Company | Round with Invus | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $135M | $335M | Oct 13, 2026 Series B+ |
Robotics and hardware |
Series A · $100M | $104.5M | Oct 8, 2026 Series A |
Health and bio |
Series B+ · $150M | $250M | Oct 7, 2026 Series B+ |
Health and bio |
Series B+ · $250M | $303M | Sep 24, 2026 Series B+ |
Health and bio |
Series B+ · $75M | $543M | Aug 6, 2026 Series B+ |
Health and bio |
Series B+ · $99.5M | $234.5M | Aug 8, 2026 Series B+ |
Health and bio |
Series B+ · $92.5M | $105.45M | Jun 2, 2026 Series B+ |
Health and bio |
Series B+ · $287M | $287M | Jan 26, 2026 Series B+ |
Health and bio |
Series B+ · $120M | $120M | Dec 3, 2025 Series B+ |
Logistics and mobility |
Series B+ · $200M | $719.2M | May 15, 2026 Series B+ |
Health and bio |
Series B+ · $260M | $260M | Jul 16, 2024 Series B+ |
Health and bio |
Series B+ · $90M | $125M | Aug 17, 2026 Series B+ |
Health and bio |
Series A · $270M | $270M | Aug 3, 2025 Series A |
Health and bio |
Series B+ | $167M | Jun 30, 2026 Series B+ |
Health and bio |
Series B+ · $112M | $171M | Nov 4, 2025 Series B+ |
Health and bio |
Series B+ · $150M | $236M | May 10, 2022 Series B+ |
Data and analytics |
Series B+ · $222M | $384.9M | Feb 24, 2022 Series B+ |
Health and bio |
Series B+ · $108M | $218M | Apr 16, 2024 Series B+ |
Climate and energy |
Series B+ · $56M · lead | $218M | May 25, 2022 Series B+ |
Voice and audio AI |
backer | $710M | Sep 29, 2026 Series B+ |
Stablecoins |
backer | $243.57M | Jan 7, 2026 round |
Health and bio |
backer | $650M | Jan 13, 2026 Series B+ |
Commerce and retail |
backer | $50M | Feb 14, 2025 Seed |
Fintech |
backer | $982M | Jan 22, 2026 Series A |
AI agents |
backer | $70M | Jun 24, 2024 round |
Most frequent co-investors
RRA Capital Management6 shared rounds · last Aug 6, 2026
GGV5 shared rounds · last Aug 6, 2026
AARCH Venture Partners5 shared rounds · last Aug 6, 2026
TThird Rock Ventures5 shared rounds · last Mar 22, 2023
NNextech Invest4 shared rounds · last Oct 7, 2026
FFidelity4 shared rounds · last Jun 8, 2026
PPolaris3 shared rounds · last Oct 13, 2026
SSofinnova Partners3 shared rounds · last Jun 8, 2026
CCasdin Capital3 shared rounds · last Jun 8, 2026
RRock Springs Capital3 shared rounds · last Jun 8, 2026
RRegeneron Ventures3 shared rounds · last Jun 8, 2026
BBoxer Capital3 shared rounds · last Sep 1, 2021
Similar investors
BBritish Business Bank26 companies · 12 deals in 12 mo
HHV Capital24 companies · 5 deals in 12 mo
AAtomico27 companies · 8 deals in 12 mo
SS3227 companies · 6 deals in 12 mo
JJanus Henderson Investors23 companies · 11 deals in 12 mo
EEmerson Collective23 companies · 6 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 24 rounds on Recent Funding that name Invus. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Invus, which is a subset of its real portfolio. API: /api/v1/investors/invus (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy